CA-ALATION
27.4.2022 15:02:07 CEST | Business Wire | Press release
New research from Alation Inc. , the leader in enterprise data intelligence solutions, reveals that the C-suite is dangerously behind in making needed investments in data and analytics. According to the latest Alation State of Data Culture Report , only 18% of data leaders expect to receive the full amount of funding they say is necessary to get or stay ahead of the competition for data and analytics, even as almost all (98%) cite needing it.
Data leaders feel the pressure to remain competitive and the Alation State of Data Culture Report has repeatedly shown a direct correlation between a strong data culture and an organisation’s ability to achieve or exceed revenue goals. More than 600 data leaders globally participated in this research study and the latest report found that organisations with a top-tier data culture remain the most likely to meet or exceed their revenue goals, as almost all (90%) did so over the past 12 months. Yet, 66% of data leaders cite company leadership as an obstacle to getting the funding they need, including 42% who say the C-suite doesn’t follow through on promised investment in programs that drive data culture.
In addition, only 29% of data leaders are very confident that their CEO understands the link between investment in data and analytics and staying ahead of the competition. This points to a strategy gap where C-level executives pay lip service to the benefits of investing in data and analytics, but don’t make it a priority, leaving organisations vulnerable to disruption.
“As awareness about data culture grows, executives and their organisations are learning how hard it is to build a solid foundation for it. Early in the life cycle of this research many either thought they were done or barely acknowledged the problem, whereas today, executives know they have a bigger hill to climb. There’s a lack of funding dedicated to creating a data culture that drives revenue and operational efficiency,” said Satyen Sangani, co-founder and CEO, Alation. “If these organisations fail to recognise the power of data-driven decision making, and don’t fund data and analytics initiatives properly, at best they’ll introduce significant risk to their organisations; at worst, be disrupted by competitors that threaten their existence.”
The Data Catalog Remains at the Heart of Establishing Data Culture
Data leaders have identified several core areas for investment to improve their organisation’s data culture, with 87% of data leaders agreeing that data catalogs are very important or essential to their efforts. This is a significant increase from 68% of data leaders in Q3 2021
, just 6 months earlier. Respondents also agree the first steps to building a data culture include creating data processes (44%), creating an inventory of existing data (43%), and fixing existing data quality
issues (38%).
Produced by Wakefield Research for Alation, the report includes the Alation Data Culture Index™ (DCI), a quantitative assessment of how well an organisation is positioned to enable data-driven decision-making across three key disciplines: data search & discovery, data literacy, and data governance. Enterprises are ranked low-, mid-, and top-tier based on how widely adopted these disciplines are across the enterprise.
For more information, download the Q1 2022 Alation State of Data Culture Report and read the blog, The Data Culture Gap : Q1 2022 State of Data Culture Report.
About the Alation State of Data Culture Report
The Alation State of Data Culture Report is a study sponsored by Alation and executed by Wakefield Research. Wakefield Research conducted a quantitative research study among 620 Data & Analytics Leaders at enterprises with 2,500+ employees in 14 markets across the US, EMEA, and APAC regions, with a minimum title requirement of Senior Director. Enterprises are polled annually regarding the progress of establishing a data culture — i.e., a culture of data-driven decision making — within their organisations, the challenges they face in embracing data-driven decision making, and the progress they have made in leveraging data to drive business value for their organisation.
About Alation
Alation is the leader in enterprise data intelligence solutions including data search & discovery, data governance, data stewardship, analytics, and digital transformation. Alation’s initial offering dominates the data catalog market. Thanks to its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation combines machine learning with human insight to successfully tackle even the most demanding challenges in data and metadata management. More than 330 enterprises drive data culture, improve decision making, and realise business outcomes with Alation including AbbVie, American Family Insurance, Cisco, Exelon, Fifth Third Bank, Finnair, Munich Re, NASDAQ, New Balance, Parexel, Pfizer, US Foods, and Vistaprint. Headquartered in Silicon Valley, Alation was named to Inc. Magazine’s Best Workplaces list and is backed by leading venture capitalists including Blackstone, Costanoa, Data Collective, Dell Technologies, Icon, ISAI Cap, Riverwood, Salesforce, Sanabil, Sapphire, and Snowflake Ventures. For more information, visit alation.com
.
About Wakefield Research
Wakefield Research supports the world’s most prominent brands and agencies, including 50 of the Fortune 100, in 90 countries. We provide quantitative, qualitative, and hybrid market research and market intelligence. Our work is regularly featured in the media.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005221/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
